Model-based gene selection shows engrailed 1 is associated with antipsychotic response

Pharmacogenetics and Genomics

Volumn 18, Issue 9, 2008, Pages 751-759

  Webb, Bradley Todd ^a,d   Sullivan, Patrick F ^c   Skelly, Tara ^c   Van Den Oord, Edwin J C G ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; Association; Clinical antipsychotic trials of intervention effectiveness; Data integration; Engrailed 1; Positive and negative syndrome scale; Schizophrenia; Secretin receptor

Indexed keywords

CLOZAPINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; EN1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; HOMEODOMAIN PROTEIN; HORMONE RECEPTOR; NEUROLEPTIC AGENT; SECRETIN RECEPTOR;

ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; DTNBP1 GENE; EN1 GENE; GENE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; PROBABILITY; SCHIZOPHRENIA; SCTR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; BIOLOGICAL MODEL; GENETIC SELECTION; GENETICS;

ANTIPSYCHOTIC AGENTS; HOMEODOMAIN PROTEINS; HUMANS; MODELS, BIOLOGICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GASTROINTESTINAL HORMONE; SCHIZOPHRENIA; SELECTION (GENETICS);

EID: 53049099461     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32830162bc     Document Type: Article

References (60)

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2:e141.
2. Sullivan PF. The genetics of schizophrenia. PLoS Med 2005; 2:e212.
3. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223.
4. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003; 73:34-48.
5. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001; 156:234-258.
6. Anokhin AP, Heath AC, Myers E, Ralano A, Wood S. Genetic influences on prepulse inhibition of startle reflex in humans. Neurosci Lett 2003; 353:45-48.
7. Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry 2000; 157:1660-1668.
8. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001; 156:117-154.
9. Willott JF, Tanner L, O'Steen J, Johnson KR, Bogue MA, Gagnon L. Acoustic startle and prepulse inhibition in 40 inbred strains of mice. Behav Neurosci 2003; 117:716-727.
10. Valdar W, Solberg LC, Gauguier D, Burnett S, Klenerman P, Cookson WO, et al. Genome-wide genetic association of complex traits in heterogeneous stock mice. Nat Genet 2006; 38:879-887.
11. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29:15-31.
12. Shields AE, Fortun M, Hammonds EM, King PA, Lerman C, Rapp R, et al. The use of race variables in genetic studies of complex traits and the goal of reducing health disparities: a transdisciplinary perspective. Am Psychol 2005; 60:77-103.
13. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276.
14. Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006; 31:2033-2046.
15. Keefe RS, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull 2003; 29:45-55.
16. Hemminger BM, Saelim B, Sullivan PF. TAMAL: an integrated approach to choosing SNPs for genetic studies of human complex traits. Bioinformatics 2006; 22:626-627.
17. Chen X, Sullivan PF. Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput. Pharmacogenom J 2003; 3:77-96.
18. Livak KJ. Allelic discrimination using fluorogenic probes and the 50 nuclease assay. Genet Anal 1999; 14:143-149.
19. Goldstein H. Multilevel statistical models. London: Arnold; 1995.
20. Searle SR, Casella G, McCuloch CE. Variance components. New York: Wiley; 1992.
21. Van den Oord EJCG. Estimating effects of latent and measured genotypes in multilevel models. Statist methods Med Res 2001; 10:393-407.
22. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003; 100:9440-9445.
23. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96:434-442.
24. Tsai CA, Hsueh HM, Chen JJ. Estimation of false discovery rates in multiple testing: application to gene microarray data. Biometrics 2003; 59:1071-1081.
25. Thomas DC, Clayton DG. Betting odds and genetic associations. J Natl Cancer Inst 2004; 96:421-423.
26. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57:289-300.
27. Storey JD. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann Stat 2003; 31:2013-2035.
28. van den Oord EJ, Sullivan PF. False discoveries and models for gene discovery. Trends Genet 2003; 19:537-542.
29. Brown BW, Russell K. Methods correcting for multiple testing: operating characteristics. Stat Med 1997; 16:2511-2528.
30. Fernando RL, Nettleton D, Southey BR, Dekkers JCM, Rothschild MF, Soller M. Controlling the proportion of false positives in multiple dependent tests. Genetics 2004; 166:611-619.
31. Korn EL, Troendle JF, McShane LM, Simon R. Controlling the number of false discoveries: application to high-dimensional genomic data. J Stat Plann Inference 2004; 124:379-398.
32. Van den Oord EJCG. Controlling false discoveries in candidate gene studies. Mol Psychiatry 2005; 10:230-231.
33. Sabatti C, Service S, Freimer N. False discovery rate in linkage and association genome screens for complex disorders. Genetics 2003; 164:829-833.
34. Hsueh H, Chen J, Kodell R. Comparison of methods for estimating the number of true null hypotheses in multiplicity testing. J Biopharm Stat 2003; 13:675-689.
35. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002; 71:337-348.
36. van den Oord EJ, Sullivan PF, Jiang Y,Walsh D, O'Neill FA, Kendler KS, et al. Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families. Mol Psychiatry 2003; 8:499-510.
37. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 2003; 72:185-190.
38. Tang JX, Zhou J, Fan JB, Li XW, Shi YY, Gu NF, et al. Family-based association study of DTNBP1 in 6p22.3 and schizophrenia. Mol Psychiatry 2003; 8:717-718.
39. Funke B, Finn CT, Plocik AM, Lake S, DeRosse P, Kane JM, et al. Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet 2004; 75:891-898.
40. Kirov G, Ivanov D, Williams NM, Preece A, Nikolov I, Milev R, et al. Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria. Biol Psychiatry 2004; 55:971-975.
41. Li T, Zhang F, Liu X, Sun X, Sham PC, Crombie C, et al. Identifying potential risk haplotypes for schizophrenia at the DTNBP1 locus in Han Chinese and Scottish populations. Mol Psychiatry 2005; 10:1037-1044.
42. Van Den BA, Schumacher J, Schulze TG, Otte AC, Ohlraun S, Kovalenko S, et al. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am J Hum Genet 2003; 73:1438-1443.
43. Weickert CS, Straub RE, McClintock BW, Matsumoto M, Hashimoto R, Hyde TM, et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 2004; 61:544-555.
44. Williams NM, Preece A, Morris DW, Spurlock G, Bray NJ, Stephens M, et al. Identification in two independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch Gen Psychiatry 2004; 61:336-344.
45. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
46. Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005; 6:109-118.
47. Carlborg O, Haley CS. Epistasis: too often neglected in complex trait studies? Nat Rev Genet 2004; 5:618-625.
48. Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet 2005; 6:287-298.
49. Satagopan JM, Elston RC. Optimal two-stage genotyping in populationbased association studies. Genet Epidemiol 2003; 25:149-157.
50. Thomas DC, Haile RW, Duggan D. Recent developments in genomewide association scans: a workshop summary and review. Am J Hum Genet 2005; 77:337-345.
51. Gourion D, Leroy S, Bourdel MC, Goldberger C, Poirier MF, Olie JP, et al. Cerebellum development and schizophrenia: an association study of the human homeogene Engrailed 2. Psychiatry Res 2004; 126:93-98.
52. Hanks M,WurstW, Anson-Cartwright L, Auerbach AB, Joyner AL. Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2. Science 1995; 269:679-682.
53. Barber JC, Maloney VK, Bewes B, Wakeling E. Deletions of 2q14 that include the homeobox engrailed 1 (EN1) transcription factor are compatible with a normal phenotype. Eur J Hum Genet 2006; 14:739-743.
54. Simon HH, Saueressig H, Wurst W, Goulding MD, O'Leary DD. Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J Neurosci 2001; 21:3126-3134.
55. Bachar-Dahan L, Goltzmann J, Yaniv A, Gazit A. Engrailed-1 negatively regulates beta-catenin transcriptional activity by destabilizing beta-catenin via a glycogen synthase kinase-3beta-independent pathway. Mol Biol Cell 2006; 17:2572-2580.
56. Alimohamad H, Sutton L, Mouyal J, Rajakumar N, RushlowWJ. The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats. J Neurochem 2005; 95:513-525.
57. Alimohamad H, Rajakumar N, Seah YH, Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005; 57:533-542.
58. Kennedy JL, Farrer LA, Andreasen NC, Mayeux R, George-Hyslop P. The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science 2003; 302:822-826.
59. EvansWE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-549.
60. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7:201-204.